Kwong-Kwok Wong

Has grant

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kwong-Kwok Wong is a Professor at the University of Texas MD Anderson Cancer Center in the United States. His research primarily focuses on ovarian and breast cancers, exploring areas such as estrogen receptor signaling, tumor microenvironment, and novel liquid biopsy markers. Recent publications include studies on the prognostic implications of signaling pathways in female cancers and the heterogeneity of tumor-stroma interactions in long-term ovarian cancer survivors.

Recent Grants

Grant: Close

Rational Development of Immune Therapy for Low-Grade Ovarian Serous Carcinoma to Overcome MEK Inhibitor Resistance

Open Date: 2019-06-01

Close Date: 2022-05-01

Grant: Close

A Novel Mouse Model for Uterine Leiomyoma

Open Date: 2017-09-13

Close Date: 2019-07-31

Grant: Close

Targeted Therapy for Ovarian Clear Cell Carcinoma

Open Date: 2014-04-01

Close Date: 2016-03-01

Grant: Close

Prognostic Markers for Juvenile Pilocytic Astrocytomas

Open Date: 2006-09-11

Close Date: 2009-08-31

Grant: Close

Genetic Analysis of Stress Responses in Soil Bacteria for Enhanced Bioremediation of Mixed Contaminants

Open Date: 1996-09-01

Close Date: 1999-08-01

Articles (12)

The translation elongation factor eEF1A promotes protein synthesis. Its methylation by METTL13 increases its activity, supporting tumor growth. However, in some cancers, a high abundance of eEF1A isoforms is associated with a good prognosis. Here, we found that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively. METTL13 and PTEN competed for interaction with eEF1A2 in the same structural domain. PTEN-bound eEF1A2 promoted the ubiquitination and degradation of the mitosis-promoting Aurora kinase A in the S and G2 phases of the cell cycle. eEF1A2 bridged the interactions between the SKP1-CUL1-FBXW7 (SCF) ubiquitin ligase complex, the kinase GSK3β, and Aurora-A, thereby facilitating the phosphorylation of Aurora-A in a degron site that was recognized by FBXW7. Genetic ablation of Eef1a2 or Pten in mice resulted in a greater abundance of Aurora-A and increased cell cycling in mammary tumors, which was corroborated in breast cancer tissues from patients. Reactivating this pathway using fimepinostat, which relieves inhibitory signaling directed at PTEN and increases FBXW7 expression, combined with inhibiting Aurora-A with alisertib, suppressed breast cancer cell proliferation in culture and tumor growth in vivo. The findings demonstrate a therapeutically exploitable, tumor-suppressive role for eEF1A2 in breast cancer.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Samuel Mok

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Junxiong Chen

University of Oklahoma Health Sciences Center

UNITED STATES
View details

David Gershenson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Susana Banerjee

Reader in Women's Cancers (Systemic Therapy and Clinical Trials)

Institute of Cancer Research

UNITED KINGDOM
View details

Eucharist Kun

University of Texas at Austin

UNITED STATES
View details

Jared Burks

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Stephanie Gaillard

Johns Hopkins University

UNITED STATES
View details

Subrata Sen

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.